MRK.US Weekly Report · 2026-W30
Weekly Overview
Merck gained 2.8% to close at $131.07 this week, reaching near-record levels. Momentum stems from multiple milestones in HIV prevention and treatment, plus FDA approval of the first oral PCSK9 cholesterol drug. Institutional ratings remain strong, yet capital flows show divergence—both major traders and retail investors posted net outflows, a contradiction worth scrutiny.
Price Action
Merck closed at $131.07, up 2.80% from the prior week’s close of $127.50 (July 17). The weekly range spanned 5.5% (high $131.71, low $124.22), with the stock climbing from a Monday open of $124.40 and peaking Thursday at $131.71 before settling Friday. The pattern reflects steady recovery followed by consolidation at higher levels.
Weekly volume reached approximately 37.55 million shares, with a turnover rate of 0.25%, matching the 60-day median—no significant volume surge or contraction. Price action remained orderly without extreme swings.
Valuation and Earnings
Current P/E of 36.23x sits at an extreme low, positioned at only the 3.6th percentile within a 5-year range, indicating deep undervaluation. The P/B of 7.06 reads as relatively elevated, a divergence reflecting near-term anxiety about earnings power.
Most recent quarter (Q1 2026) EPS came in at -$1.72, a 185.57% YoY decline resulting in a loss. Yet operating revenue of $16.29 billion grew 4.87% YoY, signaling healthy top-line performance; the loss stems from cost pressures or one-time charges. This massive gap versus the consensus EPS forecast of $6.18 suggests Q1’s negative figure likely represents a temporary trough, with subsequent quarters needing substantial sequential recovery to meet full-year expectations. If not, the annual guidance faces revision risk.
Capital Flows
Major traders: inflows $496.17, outflows $697.45, net outflow ~$200. Retail investors: inflows $3573.61, outflows $4899.97, net outflow ~$1300. Both cohorts posted net outflows, with retail outflows materially larger. This contradicts the week’s price gain—rising while capital flows out typically signals that ratings or sentiment lag the price move, or a short-term technical rebound triggering profit-taking.
Institutional Ratings
Current distribution across 28 analysts: 15 buy, 8 hold, 0 neutral, 4 reduce, 1 strong sell. Buys represent 54%, holds 29%, combined 83% positive. Consensus price target $134.62, implying 2.6% upside from current $131.07. Ranks 4th among 255 pharma companies in the industry. Ratings last updated July 23 (this week).
Caveat: Institutional ratings are lagging indicators, typically rooted in already-disclosed data and should not serve as sole decision anchors.
Weekly News Drivers
Multi-Front HIV Progress: Gilead–Merck collaboration on a once-weekly oral HIV treatment regimen suppressed virus in late-stage trials; Merck licensed its experimental HIV pill to generic manufacturers across 129 countries, accelerating global access; partnered with Aspen Pharmacare on a once-monthly HIV prevention pill (MK-8527).
First Oral PCSK9 Cholesterol Drug Approved: Merck won FDA approval for the first once-daily oral PCSK9 cholesterol agent, a first-to-market breakthrough. The approval fills a therapeutic gap and counters revenue headwinds in other pipelines, notably the oncology franchise (Keytruda).
M&A Chatter: Merck reportedly made overtures in a takeover battle, showing interest in genomics firm Personalis.
Key News Links:
- Aspen Pharmacare signs voluntary licensing deal with Merck for once-monthly HIV prevention pill MK-8527
- Merck Announces Initial Access Plans For Alimatravir In Low- And Middle Income Countries
- Merck licenses experimental HIV pill to generic makers in 129 countries
- Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill
- Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials
- Merck (MRK) Wins FDA Approval For First Once Daily Oral PCSK9 Drug
- Merck Climbs 3% to Record After FDA Approves Oral Cholesterol Drug
- Personalis is said to have attracted takeover interest from Merck
- Analyst Raises Personalis Price Target to $17 on Heightened Takeover Prospects and Maintains Buy Rating
- MSD wins FDA approval for cholesterol pill to help plug Keytruda void
Signal Alignment and Contradictions
Points of Tension:
- Stock up 2.8% + valuation at extreme lows (3.6th percentile) + strong institutional consensus (83% buy/hold) align toward a value-discovery narrative
- Counter-signal: both major and retail traders posted net outflows, hinting that institutional sentiment may lag the de-leveraging moves of lower-cost basis holders
- Q1’s massive loss (-$1.72 EPS) versus full-year consensus of $6.18 exposes lumpy earnings distribution; later quarters must deliver outsized sequential recovery to validate guidance, else revisions loom
Directional Consensus: price rebound + depressed valuation + product-line breakthroughs (HIV, PCSK9) across three dimensions point toward near-term technical recovery and medium-term multiple rerating. Yet the outflow–vs–bullish-ratings gap demands forthcoming fundamentals (Q2–Q4 margin recovery) to confirm the narrative.